Cite
HARVARD Citation
Richeldi, L. et al. (2020). Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 8 (1), pp. 25-33. [Online].